Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32937
Title: Can 68 Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?
Austin Authors: Khanna, Yash;Chinni, Vidyasagar ;Gnanasambantham, Kavitha;O'Sullivan, Richard;Ballok, Zita E;Ryan, Andrew;Ramdave, Shakher;Sivaratnam, Dinesh;Bowden, Patrick;Guerrieri, Mario;Ranasinghe, Weranja K B;Frydenberg, Mark
Affiliation: Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia
Australian Urology Associates, Malvern, Vic., Australia
Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia.
Healthcare Imaging, Richmond, Vic., Australia.
TissuPath, Mount Waverley, Vic., Australia.
Monash Health, Clayton, Vic., Australia.
Cabrini Institute, Cabrini Health, Malvern, Vic., Australia.
Icon Cancer Centre, Richmond, Vic., Australia.
GenesisCare, Footscray, Vic., Australia.
Austin Health
Northern Health, Epping, Vic., Australia.
Issue Date: Sep-2023
Date: 2023
Publication information: BJU International 2023 -09; 132(3)
Abstract: To evaluate the role of multiparametric magnetic resonance imaging (mpMRI) and Gallium-68 (68 Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) in guiding salvage therapy for patients with biochemical recurrence (BCR) post-radical prostatectomy. Patients were evaluated with paired mpMRI and 68 Ga-PSMA PET/CT scans for BCR (prostate-specific antigen [PSA] >0.2‚ÄČng/mL). Patient, tumour, PSA and imaging characteristics were analysed with descriptive statistics. A total of 117 patients underwent paired scans to investigate BCR, of whom 53.0% (62/117) had detectable lesions on initial scans and 47.0% (55/117) did not. Of those without detectable lesions, 8/55 patients proceeded to immediate salvage radiotherapy (sRT) and 47/55 were observed. Of patients with negative imaging who were initially observed, 46.8% (22/47) did not reach threshold for repeat imaging, while 53.2% were rescanned due to rising PSA levels. Of these rescanned patients, 31.9% (15/47) were spared sRT due to proven distant disease, or due to absence of disease on repeat imaging. Of the original 117 patients, 53 (45.3%) were spared early sRT due to absence of disease on imaging or presence of distant disease, while those undergoing delayed sRT still maintained good PSA responses. Of note, patients with high-risk features who underwent sRT despite negative imaging demonstrated satisfactory PSA responses to sRT. Study limitations include the observational design and absence of cause-specific or overall survival data. Our findings support the use of mpMRI and 68 Ga-PSMA PET/CT in guiding timing and necessity of salvage therapy tailored to detected lesions, with potential to reduce unnecessary sRT-related morbidity. Larger or randomized trials are warranted to validate this.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32937
DOI: 10.1111/bju.16037
ORCID: 0000-0003-1747-5814
0000-0002-5615-1815
0000-0002-4006-0388
Journal: BJU International
PubMed URL: 37190993
ISSN: 1464-410X
Type: Journal Article
Subjects: PET PSMA
biochemical recurrence
mpMRI
prostate cancer
radical prostatectomy
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.